In This Article:
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S. equity market experienced a modest decline in Q1 2025, with the S&P 500 Index falling 4.27%, while bonds showed stability with the Bloomberg U.S. Aggregate Bond Index rising 2.78%. In the first quarter, Aristotle Atlantic’s Large Cap Growth Strategy delivered -9.55% gross of fees (-9.68% net of fees), outperforming the Russell 1000 Growth Index’s -9.97% return. Security selection led the portfolio to outperform in the quarter. In addition, please check the fund’s top five holdings to know its best picks in 2025.
In its first-quarter 2025 investor letter, Aristotle Atlantic Large Cap Growth Strategy highlighted stocks such as Bio-Techne Corporation (NASDAQ:TECH). Bio-Techne Corporation (NASDAQ:TECH), with a market capitalization of $7.93 billion, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets. The one-month return of Bio-Techne Corporation (NASDAQ:TECH) was -16.33%, and its shares lost 19.95% of their value over the last 52 weeks. On April 23, 2025, Bio-Techne Corporation (NASDAQ:TECH) stock closed at $50.16 per share.
Aristotle Atlantic Large Cap Growth Strategy stated the following regarding Bio-Techne Corporation (NASDAQ:TECH) in its Q1 2025 investor letter:
"Bio-Techne Corporation (NASDAQ:TECH) detracted from performance in the first quarter on fears around National Institutes of Health (NIH) funding concerns. The Trump administration announced caps on administrative costs for NIH-funded research projects, and this has resulted in fears of a slowdown in the academic and government segment. Bio-Techne has recently stated that its view is, worst case, a possible 50 basis point headwind to growth. Bio-Techne has shown positive momentum following a strong fiscal second quarter earnings report that included organic revenue growth of 9%."
A cutting-edge laboratory with technicians in white coats studying a POC device.
Bio-Techne Corporation (NASDAQ:TECH) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 24 hedge fund portfolios held Bio-Techne Corporation (NASDAQ:TECH) at the end of the fourth quarter compared to 25 in the third quarter. In the second quarter of fiscal 2025, the company generated $297 million in revenues, up 9% year-over-year on both reported and organic basis. While we acknowledge the potential of Bio-Techne Corporation (NASDAQ:TECH) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.